{"article": [{"url": "https://www.marketwatch.com/story/avidity-biosciences-upsizes-planned-ipo-and-raises-price-range-2020-06-11", "published": 1591857380.0, "headline": "Avidity Biosciences upsizes planned IPO and raises price range", "body": "Avidity Biosciences Inc. RNA, -3.35%, a biotech the specializes in treatments for muscular disorders, upsized its planned initial public offering on Thursday and raised the price range, indicating strong demand from investors. The company said in a regulatory filing that it now plans to offer 12 million shares priced at $17 to $18 each. That's up from a previous plan to offer 10 million shares priced at $14 to $16. he company has applied to list on Nasdaq, under the ticker symbol \"RNA.\" Cowen, SVB Leerink, Credit Suisse and Wells Fargo are underwriters on the deal. Proceeds will be used to fund development of treatments for DMD and muscle atrophly, as well as for working capital. \"We are pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases,\" the company says in its IPO documents. The IPO market has come back to life with a bang in the last two weeks, after all but shutting down at the peak of the coronavirus pandemic."}]}